


#### Extended figure 1-1: Determination of Eliglustat Concentration based on lipid quantification.


GBA1<sup>+/+</sup> and GBA1<sup>+/L444P</sup> Primary cortical neurons were treated at DIV14 with varying concentrations of eliglustat (0, 1, 10, and 100 nM). Neurons were quantified by mass spectrometry for A. GlcCer (Threeway ANOVA; Interaction:  $F_{(3,151)} = 1.524$ , p=0.2106, Dose x  $\alpha$ -syn Treatment:  $F_{(3,151)} = 0.3454$ , p=0.7926, Dose x Genotype:  $F_{(3,151)} = 0.7284$ , p=0.5365, Genotype x a-syn Treatment:  $F_{(1,151)} = 3.856$ , p=0.0514, *Dose*: F<sub>(3,151)</sub>= 28.06, \*\*\*\*p<0.0001, α-syn Treatment: F<sub>(1,151)</sub>= 1.454, p=0.2299, Genotype: F<sub>(1,151)</sub>= 0.1898, p=0.6637) and **B.** sphingomyelin (*Interaction*:  $F_{(3,151)} = 0.2265$ , p=0.8778, *Dose x a-syn Treatment*: F<sub>(3,151)</sub>= 0.3922, p=0.7588, *Dose x Genotype*: F<sub>(3,151)</sub>= 0.3684, p=0.7759, *Genotype x a-syn Treatment*:  $F_{(1,151)} = 0.7365$ , p=0.3921, *Dose*:  $F_{(3,151)} = 11.11$ , \*\*\*\*p<0.0001, *a-syn Treatment*:  $F_{(1,151)} = 11.11$ , \*\*\*\*p<0.0001, \*\*\*p<0.0001, \*\*\*p>0.0001, \* 0.6928, p=0.4065, Genotype: F<sub>(1,151)</sub>= 0.08458, p=0.7716,) C. sphingosine (Interaction: F<sub>(3,157)</sub>= 1.152, p=0.3302, Dose x a-syn Treatment:  $F_{(3,157)} = 0.4860$ , p=0.6925, Dose x Genotype:  $F_{(3,157)} = 1.166$ , p=0.3245, Genotype x  $\alpha$ -syn Treatment: F<sub>(1,157)</sub>= 1.259, p=0.2636, Dose: F<sub>(3,157)</sub>= 1.922, p=0.1283,  $\alpha$ -syn *Treatment*:  $F_{(1,157)} = 0.05604$ , p=0.8132, *Genotype*:  $F_{(1,157)} = 0.5954$ , p=0.4415) and **D**. Ceramide (Interaction:  $F_{(3,151)} = 1.515$ , p=0.2128, Dose x a-syn Treatment:  $F_{(3,151)} = 0.2502$ , p=0.8611, Dose x *Genotype*:  $F_{(3,151)} = 0.2116$ , p=0.8882, Genotype x  $\alpha$ -syn Treatment:  $F_{(1,151)} = 5.610$ , \*p=0.0191, *Dose*:  $F_{(3,151)} = 4.115$ , \*\*p=0.0077, *a-syn Treatment*:  $F_{(1,151)} = 0.01056$ , p=0.9183, *Genotype*:  $F_{(1,151)} = 0.08041$ , p=0.7771). Error bars represent SEM. For GlcCer, Sphingomyelin, and Ceramide in control treated neurons, GBA1<sup>+/+</sup> N=18, GBA1<sup>+/L444P</sup> N=24, fibril treated GBA1<sup>+/+</sup> N=18, and fibril treated GBA1<sup>+/L444P</sup> neurons N=24. To analyze sphingosine for control-treated neurons, GBA1<sup>+/+</sup> fibril-treated neurons N=24. For all lipid quantitation for eliglustat treated neurons (1nM, 10nM, and 100nM), GBA1<sup>+/+</sup> N=6, GBA1<sup>+/L444P</sup> N=8, fibril treated GBA1<sup>+/+</sup> N=6, and fibril treated GBA1<sup>+/L444P</sup> N=8, apart from fibril treated GBA1+/+ at 100nM where N=5. All sample sizes depict the number of individual mice. \*p<0.05, \*\*p<0.01, and \*\*\*\*<0.0001.

## **Extended Figure 4-1**





В




9mo

12mo


6mo

3mo




**Extended Data 4-1: Evaluation of GlcCer isoform quantification.** Four isoforms of GlcCer A. GlcCer C18:0 (Two-way ANOVA; *Interaction*:  $F_{(3,50)} = 2.173$ , p=0.1028, *Age*:  $F_{(3,50)} = 12.77$ , \*\*\*\*p<0.0001, and *Genotype*:  $F_{(1,50)} = 0.2353$ , p=0.6297) **B.** GlcCer C20:0 (*Interaction*:  $F_{(3,48)} = 0.6806$ , p=0.5682, *Age*:  $F_{(3,48)} = 0.7990$ , p=0.5005, and *Genotype*:  $F_{(1,48)} = 1.619$ , p=0.2094) **C.** GlcCer C22:0 (*Interaction*:  $F_{(3,50)} = 0.3007$ , p=0.8247, *Age*:  $F_{(3,50)} = 1.027$ , p=0.3886, and *Genotype*:  $F_{(1,50)} = 2.898$ , p=0.0949) and **D.** GlcCer C24:1 (*Interaction*:  $F_{(3,50)} = 0.7606$ , p=0.5215, *Age*:  $F_{(3,50)} = 1.821$ , p=0.1554, *Genotype*:  $F_{(1,50)} = 9.377$ , \*\*\*p=0.0035) were examined in the striatum of the same mice groups and time points. Error bars represent SEM. For all lipids, 3mo GBA1<sup>+/+</sup> N= 8, 3mo GBA1<sup>+/L444P</sup> N=7 except C18:0 N=5 and C20:0 N=6, 6mo GBA1<sup>+/+</sup> N= 8 except C18=10 and C20 =7, 6mo GBA1<sup>+/L444P</sup> N=8, 9mo GBA1<sup>+/+</sup> N= 6, 9mo GBA1<sup>+/L444P</sup> N=7, 12mo GBA1<sup>+/+</sup> N=7, and 12mo GBA1<sup>+/L444P</sup> N=7.\*p<0.05, \*\*p<0.01, \*\*\*p<0.001, and \*\*\*\*<0.0001.

**Extended Figure 5-1** 




Sphingosine-1-Phosphate

Ε



Extended Data 5-1: Evaluation of lipid plasma concentrations. Plasma was collected from GBA1<sup>+/+</sup> and GBA1<sup>+/L444P</sup> at 10-months post-monomer or fibril injection. Mass Spectrometry was used to quantify A. Total GlcCer levels (Three-way ANOVA; Interaction:  $F_{(1,35)}=0.7606$ , p=0.3891, Drug Treatment x asyn Treatment:  $F_{(1,35)}=1.268$ , p=0.2677, Drug Treatment x Genotype:  $F_{(1,35)}=0.6130$ , p=0.4389, a-syn *Treatment x Genotype:* F<sub>(1,35)</sub>= 0.7431, p=0.3945, *Drug Treatment:* F<sub>(1,35)</sub>= 181.7, \*\*\*\*P<0.0001, α-syn *Treatment*:  $F_{(1,35)} = 0.9673$ , p=0.3321, *Genotype*:  $F_{(1,35)} = 0.3836$ , p=5394), **B**. GlcSph (*Interaction*:  $F_{(1,$ 0.8940, p=0.3515, Drug Treatment x  $\alpha$ -syn Treatment: F<sub>(1.35)</sub>= 0.3667, p=0.5491, Drug Treatment x Genotype:  $F_{(1,35)}=0.6867$ , p=0.4134, a-syn Treatment x Genotype:  $F_{(1,35)}=0.6519$ , p=0.4254, Drug *Treatment*:  $F_{(1,35)} = 67.97$ , \*\*\*\*p<0.0001, *a-syn Treatment*:  $F_{(1,35)} = 3.186$ , p=0.0838, *Genotype*:  $F_{(1,35)} = 67.97$ , \*\*\*\*p<0.0001, *a-syn Treatment*:  $F_{(1,35)} = 3.186$ , p=0.0838, *Genotype*:  $F_{(1,35)} = 67.97$ , \*\*\*\*p<0.0001, *a-syn Treatment*:  $F_{(1,35)} = 3.186$ , p=0.0838, *Genotype*:  $F_{(1,35)} = 67.97$ , \*\*\*\*p<0.0001, *a-syn Treatment*:  $F_{(1,35)} = 3.186$ , p=0.0838, *Genotype*:  $F_{(1,35)} = 67.97$ , \*\*\*\*p<0.0001, *a-syn Treatment*:  $F_{(1,35)} = 3.186$ , p=0.0838, *Genotype*:  $F_{(1,35)} = 67.97$ , \*\*\*\*p<0.0001, *a-syn Treatment*:  $F_{(1,35)} = 3.186$ , p=0.0838, *Genotype*:  $F_{(1,35)} = 67.97$ , \*\*\*\*p<0.0001, *a-syn Treatment*:  $F_{(1,35)} = 3.186$ , p=0.0838, *Genotype*:  $F_{(1,35)} = 67.97$ , \*\*\*\*p<0.0001, *a-syn Treatment*:  $F_{(1,35)} = 67.97$ , \*\*\*\*p<0.0001, *a-syn Treatment*:  $F_{(1,35)} = 67.97$ , \*\*\*\*p<0.0001, *a-syn Treatment*:  $F_{(1,35)} = 67.97$ , \*\*\*\* 14.87, \*\*\*p=0.0005). C. Ceramide (Interaction:  $F_{(1,35)}=0.9955$ , p=0.3253, Drug Treatment x  $\alpha$ -syn *Treatment:*  $F_{(1,35)}$ = 2.536, p=0.1203, *Drug Treatment x Genotype:*  $F_{(1,35)}$ = 5.255, \*p=0.0280, *a-syn Treatment x Genotype:* F<sub>(1,35)</sub>= 0.6352, p=0.4308, *Drug Treatment:* F<sub>(1,35)</sub>= 7.185, \*p=0.0111, α-syn *Treatment*:  $F_{(1,35)}$ = 1.582, p=0.2168, *Genotype*:  $F_{(1,35)}$ = 7.241, \*p=0.0109) **D.** Sphingomyelin (*Interaction*:  $F_{(1,35)} = 7.734$ , \*\*p=0.0087, Drug Treatment x  $\alpha$ -syn Treatment:  $F_{(1,35)} = 3.327$ , p=0.0767, Drug Treatment x Genotype:  $F_{(1,35)}$  = 3.289, p=0.0783, a-syn Treatment x Genotype:  $F_{(1,35)}$  = 8.184, \*\*p=0.0071, Drug *Treatment*:  $F_{(1,35)} = 24.29$ , \*\*\*\*p<0.0001, *a-syn Treatment*:  $F_{(1,35)} = 0.7393$ , p=0.3957, *Genotype*:  $F_{(1,35)} = 0.7393$ , p=0.3957, *Genotype*;  $F_{(1,35)} = 0.7393$ , p=0.3957, *Genotype* 2.626, p=1141), and E. Sphingosine 1-Phosphate (Interaction: F<sub>(1,32)</sub>= 0.008874, p=0.9255, Drug Treatment x  $\alpha$ -syn Treatment: F<sub>(1,32)</sub>= 3.188, p=0.0836, Drug Treatment x Genotype: F<sub>(1,32)</sub>= 0.04317, p=0.8367,  $\alpha$ -syn Treatment x Genotype: F<sub>(1,32)</sub>= 0.6178, p=0.4376, Drug Treatment: F<sub>(1,32)</sub>= 1.016, p=0.3209,  $\alpha$ -syn Treatment: F<sub>(1,32)</sub>= 9.109, \*\*p=0.0050, Genotype: F<sub>(1,32)</sub>= 0.1771, p=0.6767). GlcCer, ceramide, and sphingomyelin had GBA1<sup>+/+</sup> N=7, GBA1<sup>+/L444P</sup> N=5, fibril treated GBA1<sup>+/+</sup> N=5, and fibril treated GBA1<sup>+/L444P</sup> N=6 for control treated groups and GBA1<sup>+/+</sup> N=7, GBA1<sup>+/L444P</sup> N=5, fibril treated GBA1<sup>+/+</sup> and GBA1<sup>+/L444P</sup> N=4 for venglustat treated groups. GlcSph and sphingosine 1-Phosphate had GBA1<sup>+/+</sup> N=6, GBA1<sup>+/L444P</sup> N=4, fibril treated GBA1<sup>+/+</sup> and GBA1<sup>+/L444P</sup> N=4 venglustat treated mice. For GlcSph and sphingosine 1-phosphate, GBA1<sup>+/+</sup> N=6, GBA1<sup>+/L444P</sup> N=5, and fibril treated GBA1<sup>+/+</sup> N=5. GlcSph had fibril treated GBA1<sup>+/L444P</sup> mice N=5, whereas sphingosine 1-phosphate had N=6 for the same group. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, and \*\*\*\*<0.0001.

# 



С


#### Extended Figure 5-2: Aggregate burden in the entorhinal cortex and basolateral amygdala. A.

Representative images of GBA1<sup>+/+</sup> and GBA1<sup>+/L444P</sup> fibril-injected mice of the amygdala were captured using confocal microscopy. Scale bar =100um, zoomed photos scale bar = 50um) **B**. Quantification of p- $\alpha$ -syn in the amygdala (N=7 for GBA1<sup>+/+</sup>, N=6 for GBA1<sup>+/L444P</sup>, Mann-Whitney test: W= 11, p=0.1690). The amygdala aggregate data failed the test for normality and graphed as a scatter plot without a bar using a Mann-Whitney test. Error bars represent SEM. **C**. Representative images of GBA1<sup>+/+</sup> and GBA1<sup>+/L444P</sup> fibril-injected mice of the entorhinal cortex were captured using confocal microscopy. Scale bar =100um, zoomed photos scale bar = 50um. **D**. Quantification of p- $\alpha$ -syn in the entorhinal cortex (N=6 for GBA1<sup>+/+</sup>, and N=7 GBA1<sup>+/L444P</sup>: Independent t-test:  $t_{(11)} = 0.03628$ ; p=0.9717). Error bars represent SEM.

### **Extended Figure 5-3**




Α



**Extended figure 5-3**: **NeuN analysis of the Prefrontal Cortex. A**. 10-months after bilateral striatal injection, immunofluorescence for NeuN was performed. Representative images of GBA1<sup>+/+</sup> and GBA1<sup>+/L444P</sup> fibril-injected mice fed control or venglustat chow of the dmPFC were captured using confocal microscopy. Scale bar =100um. B. Quantification of NeuN in the dmPFC (N=6 for both control chow groups, N=4 for venglustat chow groups, Two-way ANOVA: *Interaction*:  $F_{(1,16)}$ = 0.07678, p=0.7853, *Drug Treatment*:  $F_{(1,16)}$ = 0.02827, p=0.8686, *Genotype*:  $F_{(1,16)}$ = 2.821, p=0.1124). Error bars represent SEM.

# Extended Figure 5-4



Extended Figure 5-4: Neuroinflammation of the Granule Cell layer of the dentate gyrus of the hippocampus. 10-months after bilateral striatal injection, immunofluorescence for p- $\alpha$ -syn, IgG, and MHCII was performed. Representative images of the granule cell layer of the dentate gyrus of the hippocampus of **A**. monomer-injected GBA1<sup>+/+</sup>, **B**. monomer-injected GBA1<sup>+/+</sup>, **C**. fibril-injected GBA1<sup>+/+</sup>, and **D**. fibril-injected GBA1<sup>+/+</sup> mice were captured using confocal microscopy. Scale bar =100um. N=3 for all groups.